@entity784 ( @entity784 ) of marrow is a proven method of @entity2132 ( @entity2132 ) prophylaxis in allogeneic bone marrow transplantation (BMT). Nonetheless, @entity784 is associated with an increased risk of developing @entity1071 ( @entity1071 ). Between 1986 and 1998, 241 pediatric @entity1 at the University of Iowa underwent BMT using ex vivo @entity784 of marrow from mismatched related or matched unrelated donors. Additional @entity2132 prophylaxis included antithymocyte globulin (ATG) or anti lymphocyte globulin (ALG) post transplant (in vivo @entity784 ). A total of 30 cases of @entity1071 were identified based upon a combination of clinical, histological, and immunological features. Nearly all cases occurred within 3 months post BMT. A statistically significant increase in @entity1071 incidence was noted for @entity1 treated with ATG vs ALG (33 vs 9%). While grade I-II acute @entity2132 was more common in @entity1 receiving ATG vs ALG, no difference in grade III-IV @entity2132 or overall survival was noted between the two groups. Assessment of immune recovery at various times post BMT revealed significantly fewer T cells in the ATG-treated group, suggesting the deleterious effect of ATG may be due to excessive depletion of donor-derived @entity9653 -specific cytotoxic T cells. Thus, caution should be exercised in the use of anti-T-cell antibody therapy for additional @entity2132 prophylaxis in the setting of @entity784 BMT.

Effect of in vivo lymphocyte-depleting strategies on development of XXXX in @entity1 post allogeneic bone marrow transplantation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['post transplant lymphoproliferative disorder', 'PTLD'] @entity784 :: ('MESH:D016399', 'Disease') :: ['TCD', 'T cell depletion'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft-versus-host disease'] @entity9653 :: ('10376', 'Species') :: ['Epstein-Barr virus']
@entity1071 :: (MESH:D008232,Disease) :: ['lymphoproliferative disorders']
